FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125480505> ?p ?o ?g. }

• W3125480505 endingPage "1408" @default.
• W3125480505 startingPage "1407.2" @default.
• W3125480505 abstract "Background: Although genetic and serological risk factors have been extensively studied in rheumatoid arthritis (RA), the phase of symptoms without clinical arthritis is poorly characterized. Objectives: To identify baseline clinical and immunological markers in patients with clinically suspicious arthralgia (CSA) progressing to chronic arthritis. Methods: Prospective longitudinal study of a cohort of patients with CSA. Patients are were followed up for at least 2 years, with clinical and analytical data collection by means of standardized protocols every 6 months. Inclusion criteria were an onset of symptoms ≤ 12 months, inflammatory arthralgias involving small joints of hands or feet (predominantly in nights or mornings, improving throughout the day or with movement, and morning stiffness ≥30 min). Patients with clinical synovitis, diagnosis of fibromyalgia or osteoarthritis at baseline visit were excluded from the study. Results: 45 patients were recruited from November 2015 in our CSA clinics. The majority were women (42 patients), with a mean age at entry of 44 ± 13 years, a mean duration of symptoms before entry of 32.3 ± 15.1 weeks, and a mean follow-up time of follow-up of 17.2 ± 13.3 months. A third (30%) of patients had a family history of autoimmune diseases, 18.6% were seropositive, an average body mass index (BMI) of 27.6 ± 6.6, and 14 (31.3%) were smokers or ex-smokers. Most patients reported a progression of arthralgia over time (53%) and a joint swelling (57%). Out of 45 patients, 18 (40%) developed clinical arthritis or autoimmune disease (11 RA, 2 undifferentiated arthritis, 3 spondyloarthritis, 2 undifferentiated connective diseases), after 7 ± 8.6 months of follow-up. Among patients with ≥ 6 months follow-up, 47.1% progressed to a clinical arthritis (CA). CA patients had a longer follow-up time (22.4 ± 13.9 vs. 16.8 ± 13 months; p = 0.015), and a higher frequency of smoking (60 vs. 21.7%; p = 0.037). Likewise, CA patients presented a higher age at baseline, family history of autoimmune disease and higher baseline scores of HAQ, PGA and VAS pain, although without statistical significance (Table 1). In the subset of patients with a final diagnosis of RA, patients presented a significantly longer follow-up, and higher scores of baseline VAS pain compared to non-progressors (Table 2). Table 1. Baseline characteristics of patients Arthritis (N=18 ) No arthritis (N=27 ) p Age at onset (years) 48.5±12.1 41.2±12.5 0.06 Time of follow-up (months ± SD) 22.4±13.9 16.8±13.0 0.02 FR and / or ACPA (+) 5 (31.3%) 7 (31.8%) 0.70 Smokers / former smokers 9 (60%) 5 (21.7%) 0.04 Familial history of autoimmune disease 5 (27.8%) 4 (15.4%) 0.65 HAQ 6.5±7.0 3.6±4.5 0.20 VAS pain 46.6±35 33.4±18.5 0.17 PGA 40.2±30.5 29.6±23.2 0.28 BMI 24.3±4.2 27.1±7.4 0.18 Increased levels of acute phase reactants 31.3% 31.8% 1.00 VAS: visual analogue scale; PGA: patient global assessment; BMI: body mass index Table 2. Baseline characteristics of patients with RA vs. no arthritis RA (N=11 ) No arthritis (N=27 ) p Age at onset (years) 48.9±11.4 41.2±12.5 0.09 Time of follow-up (months ± SD) 25.5±15.6 12.8±10.9 0.01 FR and / or ACPA (+) 36.4% 16.7% 0.23 Smokers / former smokers 44.4% 21.7% 0.23 Familial history of autoimmune disease 22.2% 17.4% 1.00 HAQ 8.5±8.1 3.8±4.5 0.08 VAS pain 58.2±31.9 33.4±18.5 0.02 PGA 49.7±23.7 29.6±23.2 0.08 BMI 24±4.9 27.1±7.4 0.25 Increased levels of acute phase reactants 36.4% 16.7% 0.23 VAS: visual analogue scale; PGA: patient global assessment; BMI: body mass index Conclusion: In our CSA clinic, 40% of the patients progressed to clinical arthritis, while almost half of those who were followed for more than 6 months progressed. PROs are important to consider as markers of future development of RA. It is necessary to expand the number of patients recruited to obtain more robust conclusions. Disclosure of Interests: Laura Nuño: None declared, Diana Peiteado: None declared, Irene Monjo: None declared, Alejandro Villalva: None declared, Marta Novella-Navarro: None declared, Maria-Eugenia Miranda-Carus Grant/research support from: BMS, Roche, Paula Fortea-Gordo Grant/research support from: BMS, Maria-Jose Santos-Bornez Grant/research support from: BMS, Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Alejandro Balsa Grant/research support from: BMS, Roche, Consultant of: AbbVie, Gilead, Lilly, Pfizer, UCB, Sanofi, Sandoz, Speakers bureau: AbbVie, Lilly, Sanofi, Novartis, Pfizer, UCB, Roche, Nordic, Sandoz" @default.
• W3125480505 created "2021-02-01" @default.
• W3125480505 creator A5002285530 @default.
• W3125480505 creator A5004951927 @default.
• W3125480505 creator A5008632851 @default.
• W3125480505 creator A5011600396 @default.
• W3125480505 creator A5015000553 @default.
• W3125480505 creator A5020459487 @default.
• W3125480505 creator A5025235912 @default.
• W3125480505 creator A5047578354 @default.
• W3125480505 creator A5054608926 @default.
• W3125480505 creator A5080940624 @default.
• W3125480505 date "2020-06-01" @default.
• W3125480505 modified "2023-10-14" @default.
• W3125480505 title "AB0214 4-YEAR EXPERIENCE OF AN OUTPATIENT CLINIC OF PATIENTS WITH CLINICALLY SUSPECTED ARTHRALGIAS OF EVOLVING TO ARTHRITIS" @default.
• W3125480505 doi "https://doi.org/10.1136/annrheumdis-2020-eular.3977" @default.
• W3125480505 hasPublicationYear "2020" @default.
• W3125480505 type Work @default.
• W3125480505 sameAs 3125480505 @default.
• W3125480505 citedByCount "0" @default.
• W3125480505 crossrefType "journal-article" @default.
• W3125480505 hasAuthorship W3125480505A5002285530 @default.
• W3125480505 hasAuthorship W3125480505A5004951927 @default.
• W3125480505 hasAuthorship W3125480505A5008632851 @default.
• W3125480505 hasAuthorship W3125480505A5011600396 @default.
• W3125480505 hasAuthorship W3125480505A5015000553 @default.
• W3125480505 hasAuthorship W3125480505A5020459487 @default.
• W3125480505 hasAuthorship W3125480505A5025235912 @default.
• W3125480505 hasAuthorship W3125480505A5047578354 @default.
• W3125480505 hasAuthorship W3125480505A5054608926 @default.
• W3125480505 hasAuthorship W3125480505A5080940624 @default.
• W3125480505 hasBestOaLocation W31254805051 @default.
• W3125480505 hasConcept C126322002 @default.
• W3125480505 hasConcept C1862650 @default.
• W3125480505 hasConcept C188816634 @default.
• W3125480505 hasConcept C198451711 @default.
• W3125480505 hasConcept C2776260265 @default.
• W3125480505 hasConcept C2776821229 @default.
• W3125480505 hasConcept C2777077863 @default.
• W3125480505 hasConcept C2777575956 @default.
• W3125480505 hasConcept C2777831278 @default.
• W3125480505 hasConcept C2779244835 @default.
• W3125480505 hasConcept C2780221984 @default.
• W3125480505 hasConcept C3020110884 @default.
• W3125480505 hasConcept C71924100 @default.
• W3125480505 hasConcept C72563966 @default.
• W3125480505 hasConceptScore W3125480505C126322002 @default.
• W3125480505 hasConceptScore W3125480505C1862650 @default.
• W3125480505 hasConceptScore W3125480505C188816634 @default.
• W3125480505 hasConceptScore W3125480505C198451711 @default.
• W3125480505 hasConceptScore W3125480505C2776260265 @default.
• W3125480505 hasConceptScore W3125480505C2776821229 @default.
• W3125480505 hasConceptScore W3125480505C2777077863 @default.
• W3125480505 hasConceptScore W3125480505C2777575956 @default.
• W3125480505 hasConceptScore W3125480505C2777831278 @default.
• W3125480505 hasConceptScore W3125480505C2779244835 @default.
• W3125480505 hasConceptScore W3125480505C2780221984 @default.
• W3125480505 hasConceptScore W3125480505C3020110884 @default.
• W3125480505 hasConceptScore W3125480505C71924100 @default.
• W3125480505 hasConceptScore W3125480505C72563966 @default.
• W3125480505 hasIssue "Suppl 1" @default.
• W3125480505 hasLocation W31254805051 @default.
• W3125480505 hasOpenAccess W3125480505 @default.
• W3125480505 hasPrimaryLocation W31254805051 @default.
• W3125480505 hasRelatedWork W1495854428 @default.
• W3125480505 hasRelatedWork W2060696276 @default.
• W3125480505 hasRelatedWork W2243605599 @default.
• W3125480505 hasRelatedWork W2322008021 @default.
• W3125480505 hasRelatedWork W2326942785 @default.
• W3125480505 hasRelatedWork W2394586447 @default.
• W3125480505 hasRelatedWork W2743764001 @default.
• W3125480505 hasRelatedWork W2947629097 @default.
• W3125480505 hasRelatedWork W3097954487 @default.
• W3125480505 hasRelatedWork W3125480505 @default.
• W3125480505 hasVolume "79" @default.
• W3125480505 isParatext "false" @default.
• W3125480505 isRetracted "false" @default.
• W3125480505 magId "3125480505" @default.
• W3125480505 workType "article" @default.